MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 154 participants.
Also called NCT05409989
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 154 participants
- Sponsor
- Registry
-
NCT05409989
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05409989. Allocation not applicable; no masking; primary purpose treatment. Start 2022-09-20 (actual); primary completion 2027-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study
- Condition
- Intracranial Aneurysm
- Intervention (Device)
- FRED™ X™
- Lead sponsor
- Microvention-Terumo, Inc.
Record details
- Record id
cardio:ct-nct05409989- Content hash
53c260a959d603faaea8d4ac551d1c54947a1d8ab7fe2906f715a9afc61223ee